Compare Gilead Sciences, Inc. (GILD) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while YieldMax Universe Fund of Option Income ETFs trades at $7.66. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| GILD | YMAX | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $14.00 |
52-Week Low | $108.22 | $7.51 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
YMAX trades at $7.73, down 2.15% in the last session. The technical outlook is bearish with all moving average signals indicating selling pressure. Recent news highlights concerns over the fund's fee structure and shrinking distributions, while weekly dividend announcements continue. The stock shows consistent dividend payments but lacks fundamental ratio data for deeper valuation analysis.
The outlook remains cautious due to bearish technicals and cost structure criticisms. Investment appeal hinges on income from dividends, but risks include fee erosion and weak price momentum. Investors should weigh the high yield against potential capital depreciation and structural costs highlighted by financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
